# Title: Association between Positive Airway Pressure Adherence and Healthcare Costs

### Short-title: Positive Airway Pressure Adherence and Costs

<u>Authors</u>: Jaejin An<sup>1</sup>, Henry A. Glick<sup>2</sup>, Amy M. Sawyer<sup>3,4</sup>, Jessica Arguelles<sup>5</sup>, Charles J. Bae<sup>6</sup>, Aiyu Chen<sup>1</sup>, Brendan T. Keenan<sup>6</sup>, Samuel T. Kuna<sup>4,5</sup>. Greg Maislin<sup>6</sup>, Diego R. Mazzotti<sup>7</sup>, Allan I. Pack<sup>6</sup>, Jiaxiao M. Shi<sup>1</sup>, Alexa J. Watach<sup>3</sup>, Dennis Hwang<sup>5</sup>

<u>Affiliations</u>: <sup>1</sup>Department of Research & Evaluation, Kaiser Permanente Southern California; <sup>2</sup>Department of Medicine, Perelman School of Medicine, University of Pennsylvania; <sup>3</sup>Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania; <sup>4</sup>Corporal Michael J. Crescenz Veterans Affairs Medical Center; <sup>5</sup>Sleep Medicine, Southern California Medical Group; <sup>6</sup>Division of Sleep Medicine, Department of Medicine, University of Pennsylvania; <sup>7</sup>Division of Medical Informatics, Department of Internal Medicine, University of Kansas Medical Center

#### **Corresponding author:**

Dennis Hwang, MD 9961 Sierra Ave, Fontana, CA 92335 Dennis.x.hwang@kp.org Phone: 909-427-4432 Fax: 909-427-5664

# **Key Words List**

Obstructive sleep apnea, Positive airway pressure, Adherence, Cost and cost analysis

# **Abbreviation List**

- AHI: Apnea Hypopnea Index
- ANOVA: analysis of variance
- BMI: body mass index
- **CPT: Current Procedural Terminology**
- DME: durable medical equipment
- GLM: generalized linear models
- HCPCS: Healthcare Common Procedure Coding System
- NADAC: National Average Drug Acquisition Cost
- OSA: Obstructive sleep apnea
- PAP: positive airway pressure

#### Abstract

**Background**: The impact of positive airway pressure (PAP) therapy for obstructive sleep apnea (OSA) on healthcare costs is uncertain.

**Research Question**: Are three-year healthcare costs associated with PAP adherence in participants from the Tele-OSA clinical trial?

**Study Design and Methods**: Participants with OSA and prescribed PAP in the Tele-OSA study were stratified into three PAP adherence groups based on usage patterns over three years: (a) high (consistently  $\geq$ 4 hours/night); (b) moderate (2-3.9 hours/night or inconsistently  $\geq$ 4 hours/night); (c) low (<2 hours/night). Using data from three months of the Tele-OSA trial and 33 months of post-trial follow-up, average healthcare costs (2020 US dollars) in six-month intervals were derived from electronic health records and analyzed using multivariable generalized linear models.

**Results**: Of 543 participants, 25% were categorized as having high adherence, 22% moderate adherence, and 52% low adherence to PAP therapy. Average (standard deviation) PAP use was 6.5 (1.0) hours, 3.7 (1.2) hours, and 0.5 (0.5) hours for the high, moderate, and low adherence groups, respectively. The high adherence group had the lowest average [standard error] covariate-adjusted six-month healthcare costs (\$3,162 [\$240]) compared with the moderate (\$3,658 [\$369]) and low (\$4,016 [\$315]) adherence groups. Significant cost savings were observed between the high and low adherence groups (\$854 [95% CI \$158, \$1,551]); savings between moderate and low adherence were non-significant (\$359 [95% CI -\$459, \$1,176]).

**Interpretation**: In participants with OSA, better PAP adherence was associated with significantly lower healthcare costs over three years. Findings support the importance of strategies to enhance long-term PAP adherence.

Obstructive sleep apnea (OSA) carries substantial public health implications given its high prevalence and associations with co-morbid medical conditions. OSA affects approximately 26% of adults between the ages of 30 and 70 years in the United States and 1 billion persons worldwide [1, 2]. Furthermore, it is strongly linked to a broad range of cardiometabolic conditions including hypertension, diabetes, arrhythmias, heart failure, stroke, acute cardiovascular events, and death [3-12]. The impact of OSA on mental health and various components of daytime functioning such as excessive daytime somnolence is also well-established resulting in increased risk of psychiatric disorders, motor vehicle accidents, and work absenteeism [13-22]. As a result, OSA is understood to directly and indirectly impact patient, societal, and healthcare costs [23-43].

The increase in health-related costs is reflected in a broad spectrum of services affecting inpatient, outpatient, emergency, and pharmacy-related costs [34, 43-45]. Conceptually, positive airway pressure (PAP) therapy should mitigate the impact of OSA on healthcare utilization; however, the overall body of evidence is limited and its results are mixed [34, 44-47]. Furthermore, recent technological advances in PAP devices have resulted in the ability to remotely monitor objective measures of PAP adherence over time. These measures are important when investigating the relationship between PAP adherence and cost because as few as 30-40% of patients have been reported to maintain substantial use after 1 year [48].

In this study, we used data from the Tele-OSA randomized clinical trial that evaluated the impact of an automated telemonitoring mechanism on improving PAP adherence [48]. The goal of this *post hoc* analysis is to evaluate the relationship between three levels of long-term PAP adherence and three-year healthcare cost.

#### Methods

### Clinical Trial

Data for our analysis were drawn from the Tele-OSA study, a four-arm factorial design randomized clinical trial that enrolled participants from 2015 to 2016. The study investigated the impact of two telehealth mechanisms on PAP adherence: (a) remote delivery of an automated digital OSA educational program (Emmi Solutions, Inc), and (b) automated PAP telemonitoring with participant feedback messaging (see **e-Figure 1**). A total of 1,455 participants were enrolled in the study, of which 556 agreed to participate in the PAP trial and accept PAP therapy. Study results revealed significantly improved three-month PAP adherence (primary endpoint of the Tele-OSA study) in participants receiving telemonitoring [48]. Epidemiologic follow-up based on electronic health records was continued for an additional 33 months, for a total follow-up of three years. *Post-hoc* analysis demonstrated improved PAP use at one year with continued feedback messaging [49].

#### **Ethics**

The Tele-OSA study and all subsequent analyses based on the study cohort were approved by the Kaiser Permanente Southern California Institutional Review Board. Participant written informed consent was waived for the entire study, including the epidemiologic follow-up, due to the minimal risk of the study interventions and data collection procedures.

### Study Population

Of the 1,455 trial enrollees, we included participants with OSA (apnea hypopnea index ≥5 events/hour) who were prescribed PAP. To ensure sufficient cost data for our analysis, we excluded participants without six months or longer continuous health plan eligibility during the three-year follow-up period.

### PAP Adherence

Hours of PAP use were derived from an auto-titrating device (AirSense 10; ResMed Corp) capable of wirelessly transmitting PAP data daily via a cellular signal into a cloud database (U-Sleep; ResMed Corp). We created PAP adherence groups by consolidating eligible participants from all study arms and used these data to stratify them into high, moderate, and low use groups. We considered two dimensions of PAP adherence to construct these categories—hours/night of daily use and consistency of use throughout the three years of follow-up.

The high adherence group consisted of participants who used PAP an average of  $\geq$ 4 hours/night consistently for every six-month interval over three years. The moderate adherence group consisted of participants who either used PAP for an overall average

of 2-3.9 hours/night over three years or who used PAP for  $\geq$ 4 hours/night overall, but had at least one six-month interval with <4 hours/night of average use (i.e., inconsistent use). The low adherence group consisted of participants who used PAP an average of <2 hours/night over three years, independent of whether they had any six-month intervals with >4 hours/night.

#### Healthcare Costs

The trial was performed in an integrated healthcare system that allowed access to nearcomprehensive healthcare utilization information maintained in electronic health records. Healthcare costs (2020 US dollars) were derived by assigning nationally representative cost estimates to this utilization. Recorded healthcare services included sleep-related and non-sleep-related office visits, sleep-related and non-sleep-related durable medical equipment (DME), hospitalizations, other hospital visits (e.g., observation bed, same-day discharge after minimally invasive surgery), pharmacy, laboratory tests, emergency department visits, radiology visits, and phone encounters. Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) Codes were used to assign cost estimates from 2020 Medicare fee schedules for each service other than hospitalization and pharmacy [50-52]. Sleeprelated CPT codes and Medicare fee schedules are shown in **eTable 1**. For pharmacy costs, we used Medicaid National Average Drug Acquisition Cost (NADAC) data to assign costs to each National Drug Code or generic name per prescription [53]. For hospitalizations, we used data from the National Inpatient Sample to derive an average

cost per day for each Diagnosis Related Group code and multiplied it by participants' lengths of stay [54]. The Consumer Price Index Medical Care component was applied to convert all hospitalization costs to 2020 US dollars [55].

#### Statistical Analysis

We compared participant sociodemographic and clinical characteristics among the PAP adherence groups using analysis of variance (ANOVA) for continuous variables and Chi-square tests for categorical variables. They were also used for the evaluation of average (SD) hours/night of PAP use and healthcare costs within six-month intervals during the three years of follow-up. Trends over time were tested using non-parametric Jonckheere-Terpstra tests.

Adjusted six-month average healthcare costs by adherence group were estimated using repeated measures generalized linear models (GLM) that accounted for within-subject correlations. Covariates included age, sex, race/ethnicity, body mass index (BMI) category, Medicaid enrollment, smoking, Apnea Hypopnea Index (AHI) category (5-14.9, 15-29.9, 30 or higher), hypertension, Charlson comorbidity score, mild liver disease, pre-operative referral to sleep clinic prior to randomization, log transformed prior six-month cost, and time indicators representing the six-month interval (i.e. months 1-6, months 7-12, etc.). To address bias due to censoring (e.g., lost membership during follow-up), we applied inverse probability of censoring weights estimated by use of logistic regression [56, 57]. For the GLM model predicting total cost as well as for the models predicting subtypes of costs (e.g., hospitalization and pharmacy), we used the

modified Park, Pregibon link, Pearson correlation, and modified Hosmer and Lemeshow tests to select families and links [58]. For example, the resulting recommended link for the estimation of total costs was power = -0.3 and family was gamma.

An *a priori* stratified analysis was conducted by OSA severity (AHI 5-14.9 and 15 or higher). Effect modification by OSA severity was formally tested using statistical interaction tests. Sensitivity analysis was conducted after excluding participants who were referred to sleep clinic prior to any planned surgery.

All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC) or Stata 15.1 (StataCorp LLC, College Station, TX). Given our single primary outcome of total costs, a *p*<0.05 was considered statistically significant.

#### Results

Of the 1,455 participants that were enrolled in the Tele-OSA study, we excluded 372 participants with an AHI <5, 531 who had an AHI >5 and were not prescribed PAP therapy, and an additional 9 participants for not having at least six months of continuous eligibility. Of the remaining 543 participants, 138 (25%) were categorized as having high adherence to PAP therapy, 120 (22%) moderate adherence, and 285 (52%) low adherence.

Participant sociodemographic and clinical characteristics overall and by PAP adherence groups are shown in **Table 1**. The sample was middle aged (mean [SD] age 50.0 [12.1] years) and obese (BMI of 35.3 [7.5] kg/m<sup>2</sup>) on average, and 59% were male. A greater proportion of the high adherence group was comprised of whites compared with the low

and moderate adherence groups. Mean AHI scores were higher for the high adherence group than for the low or moderate adherence groups, although all groups had moderate/severe disease on average. Other characteristics were similar across PAP adherence groups.

Average (SD) hours of PAP use were 6.5 (1.0), 3.7 (1.2), and 0.5 (0.5) hours/night for the high, moderate, and low adherence groups, respectively. **Figure 1** and **e-Table 2** show the three groups' average hours of PAP use for each six-month interval over the three years of follow-up. For the low and moderate adherence groups, average use was highest initially and decreased with time (p<0.001). On the other hand, the high adherence group started with high use and showed significantly increased use over time (p<0.001).

**Figure 2** and **e-Table 3** show average unadjusted healthcare costs over time. The sixmonth average cost prior to randomization (i.e., before OSA diagnosis and PAP initiation, represented by the left-most bar of each of the three clusters) was similar across the three adherence groups (p=0.91). The six-month average cost post to randomization in the high adherence group were significantly lower than those in the low adherence group (p=0.002) (**e-Table 3**), while differences between the moderate and low adherence groups (p=0.38) or between the high and moderate groups (p=0.08) were not statistically significant.

**Table 2** and **e-Table 4** show the adjusted average (SE) six-month costs by PAP adherence group for the overall sample as well as stratified by AHI. As with the unadjusted results, compared with the low adherence group, the high adherence group had significant adjusted six-month cost savings of \$854 (95% CI (\$158 to \$1,551,

p=0.01). Similarly, neither the adjusted difference in cost between the moderate and low adherence groups nor between the moderate and high adherence groups differed significantly.

**Table 3** shows adjusted average six-month healthcare costs subdivided into 11 categories. The significantly lower overall cost in the high versus low adherence groups was due to significant savings in 5 of 11 cost categories: sleep-related office visit, non-sleep-related office visit, hospitalization, laboratory, and phone encounters while being slightly offset by a significant increase in sleep-related DME costs. The only three categories for which the high adherence group differed significantly from the moderate group were hospitalization, phone, and non-sleep-related DME. Finally, compared to the low adherence group, the moderate adherence group had significantly higher sleep-related DME costs.

An interaction test examining whether the cost savings associated with specific adherence groups differed based on AHI severity was non-significant (p=0.06). However, given the limited power of this test, we also performed an *a priori* specified stratified analysis. Results showed that among participants with mild OSA (AHI 5-14.9), the high and moderate adherence groups both had significant savings compared to the low group (\$938, 95% CI \$148 to \$1,819, p=0.02 for high vs low and \$1,257, 95% CI \$369 to \$2,145, p=0.006 for medium vs low). There were, however, no significant differences between the high and moderate groups. Unlike the findings for those with mild OSA, among participants with moderate to severe OSA (AHI ≥15), there were no statistically significant differences between any of the three adherence groups. Finally, in sensitivity analysis, findings were consistent after the exclusion of participants who were referred to sleep clinic prior to planned surgery (see **e-Table 4**).

#### Discussion

The current study evaluated healthcare costs associated with PAP adherence among participants in the Tele-OSA clinical trial. Using daily PAP use data over a three-year follow-up period, this study stratified participants into high, moderate, and low long-term adherers to PAP therapy. The integrated healthcare system with electronic health records captured all aspects of care; therefore, we were able to evaluate the relationship between PAP adherence and healthcare costs across a broad range of services. Our results demonstrated lower healthcare costs associated with high adherence compared with low adherence supporting the potential economic benefits of PAP therapy.

Although OSA is understood to impact healthcare costs through its association with cardiovascular disease, mental health disorders, peri-operative risk, and rate of hospitalizations [8, 19, 59]., there has been lack of economic evaluation studying the potential impact of PAP use. Furthermore, the few previous studies have not consistently reported a beneficial association between PAP therapy and cost. An earlier study from the Kaiser Permanente healthcare delivery system failed to demonstrate a significant impact of PAP dispensation on acute care and pharmacy utilization, although PAP adherence was not available to be included in the analysis [46]. A recent study by Kirsch *et al.* reported that use of PAP at least 4 hours/night over an 18-month period in

participants with moderate-severe OSA was associated with lower inpatient visits and costs compared with non-adherers [44]. Our study adds to the body of evidence that long-term adherence to PAP therapy can beneficially impact healthcare costs.

Several interesting patterns emerged from this study that warrant further investigation. First, mimicking the findings in the Kirsch et al study, savings appeared to be driven by reduced cost related to hospitalizations. Further understanding the specific services for which there are savings from PAP therapy carries potential implications in developing administrative and clinical care strategies. Second, PAP use among participants with mild OSA was observed to result in greater cost savings than among those with moderate-severe OSA. While this apparent reverse dose-response pattern should be replicated within larger samples, the results are supportive of the hypothesis that treating participants with mild OSA may be clinically important. Future confirmation of this finding could influence approaches to clinical care and development of research cohorts that currently tend to focus on moderate-severe OSA. Third, PAP adherence stratification was based not only on absolute usage but also on the consistency of maintaining adherence over time. Cost reductions realized among high adherers but not clearly evident among moderate adherers are suggestive of the hypothesis that both sufficient and consistent use are important to improve outcomes. Our data also highlight the challenge of meeting both adherence targets—only 25% of the analysis cohort used PAP consistently ≥4 hours/night over three years. Further understanding the influence of PAP adherence patterns on healthcare outcomes is important in strategizing effective clinical care follow-up protocols.

This study has several potential limitations. First, although we adjusted for participant sociodemographic and clinical characteristics as covariates, there may be unmeasured confounders. In particular, healthy adherer bias is a typical concern in the adherence literature [60-63]; participants adherent to PAP therapy may also be more likely to adhere to other medical care (e.g., medication use or receiving preventative therapy) or healthy lifestyle behaviors (e.g., diet and exercise). However, our assessment of medication adherence at baseline as well as six-month healthcare costs prior to randomization were similar across PAP adherence groups. Second, our study population was comprised of clinical trial participants which could limit generalizability to real-world populations. However, the Tele-OSA study was conducted in a pragmatic setting that enrolled participants at risk for OSA typical of a standard sleep medicine practice, which helps mitigate the potential limits in generalizability. Third, there may be misclassification bias [64]. We used diagnosis codes from electronic health records to define comorbidities; therefore, comorbidities of participants who did not interact with the healthcare system or participants without continuous eligibility may have not been fully captured. However, 86% of the study population had continuous eligibility for 12 months prior to the index date, and all participants had at least one interaction with the healthcare system. Fourth, we evaluated healthcare costs by assigning nationally representative costs instead of paid claims. However, this approach is recognized as a generalizable method to other healthcare settings [58, 65].

#### Interpretation

Better PAP adherence (consistent PAP use of  $\geq$ 4 hours/night) was associated with significantly lower healthcare costs over three years in participants with OSA. Findings

support the importance of care strategies to enhance long-term PAP adherence for

OSA therapy.

### Acknowledgments

#### Guarantor

Hwang takes responsibility for the content of the manuscript, including the data and analysis

### **Author Contributions**

An contributed to the study design, data analysis, interpretation, and initial draft of the manuscript. Glick, Sawyer contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. Arguelles, Chen, Shi contributed data acquisition, programming, data analysis, and the critical revision of the manuscript. Bae, Keenan, Kuna, Maislin, Mazzotti, Pack, Watach contributed to the study design, interpretation, and the critical revision of the manuscript. Hwang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

### **Financial Disclosure**

An, Bae, Glick: No conflicts to disclose

Hwang: Research funding from AASM Foundation, National Institutes of Health, and Kaiser Permanente Southern California Research and Evaluation Clinical Investigator Program.

Sawyer: Research funding from National Institutes of Health and Veterans Affairs HSR&D.

Mazzotti: Research funding from AASM Foundation, American Heart Association and National Institutes of Health.

Watach: Research training supported by National Institutes of Health.

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

# **Role of the Sponsors**

Not applicable

### **Prior Abstract Publication/Presentation**

Preliminary findings were presented as a poster at Virtual Sleep, 2021 (June 10-13, 2021). An J, Glick H, Shi J, Chen A, Arguelles J, Keenan B, Maislin G, Mazzotti D, Sawyer A, Pack A, Hwang D. Association between Positive Airway Pressure Adherence and Healthcare Costs, Sleep, Volume 44, Issue Supplement\_2, May 2021, Page A177, https://doi.org/10.1093/sleep/zsab072.447

#### References

 Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med.* Aug 2019;7(8):687-698. doi:10.1016/S2213-2600(19)30198-5

2. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol*. May 1 2013;177(9):1006-14. doi:10.1093/aje/kws342

3. Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population-a review on the epidemiology of sleep apnea. *J Thorac Dis.* Aug 2015;7(8):1311-22. doi:10.3978/j.issn.2072-1439.2015.06.11

 Appleton SL, Vakulin A, Wittert GA, et al. The association of obstructive sleep apnea (OSA) and nocturnal hypoxemia with the development of abnormal HbA1c in a population cohort of men without diabetes. *Diabetes Res Clin Pract*. Apr 2016;114:151-9. doi:10.1016/j.diabres.2015.12.007

5. Botros N, Concato J, Mohsenin V, Selim B, Doctor K, Yaggi HK. Obstructive sleep apnea as a risk factor for type 2 diabetes. *Am J Med.* Dec 2009;122(12):1122-7. doi:10.1016/j.amjmed.2009.04.026

 Kwon Y, Gharib SA, Biggs ML, et al. Association of sleep characteristics with atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. *Thorax*. Sep 2015;70(9):873-9. doi:10.1136/thoraxjnl-2014-206655

 Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. *JAMA*. May 23 2012;307(20):2169-76. doi:10.1001/jama.2012.3418 8. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet.* Mar 19-25 2005;365(9464):1046-53. doi:10.1016/S0140-6736(05)71141-7

9. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. *Am J Respir Crit Care Med*. Apr 15 2006;173(8):910-6. doi:10.1164/rccm.200509-1442OC

10. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med*. May 11 2000;342(19):1378-84. doi:10.1056/NEJM200005113421901

11. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. *J Am Coll Cardiol*. Apr 17 2007;49(15):1625-1631. doi:10.1016/j.jacc.2006.12.046

12. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med*. Nov 10 2005;353(19):2034-41. doi:10.1056/NEJMoa043104

13. Accattoli MP, Muzi G, dell'Omo M, et al. [Occupational accidents, work performance and obstructive sleep apnea syndrome (OSAS)]. *G Ital Med Lav Ergon*. Jul-Sep 2008;30(3):297-303. Infortuni e performances sul lavoro in lavoratori affetti da sindrome delle apnee ostruttive nel sonno (OSAS).

14. Akashiba T, Kawahara S, Akahoshi T, et al. Relationship between quality of life and mood or depression in patients with severe obstructive sleep apnea syndrome. *Chest.* Sep 2002;122(3):861-5. doi:10.1378/chest.122.3.861

15. Baldwin CM, Griffith KA, Nieto FJ, O'Connor GT, Walsleben JA, Redline S. The association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health Study. *Sleep*. Feb 1 2001;24(1):96-105. doi:10.1093/sleep/24.1.96

16. Ellen RL, Marshall SC, Palayew M, Molnar FJ, Wilson KG, Man-Son-Hing M. Systematic review of motor vehicle crash risk in persons with sleep apnea. *J Clin Sleep Med.* Apr 15 2006;2(2):193-200.

17. Mulgrew AT, Ryan CF, Fleetham JA, et al. The impact of obstructive sleep apnea and daytime sleepiness on work limitation. *Sleep Med*. Dec 2007;9(1):42-53.

doi:10.1016/j.sleep.2007.01.009

18. Omachi TA, Claman DM, Blanc PD, Eisner MD. Obstructive sleep apnea: a risk factor for work disability. *Sleep*. Jun 2009;32(6):791-8. doi:10.1093/sleep/32.6.791

 Peppard PE, Szklo-Coxe M, Hla KM, Young T. Longitudinal association of sleeprelated breathing disorder and depression. *Arch Intern Med.* Sep 18 2006;166(16):1709-15. doi:10.1001/archinte.166.16.1709

20. Hirsch Allen AJM, Bansback N, Ayas NT. The effect of OSA on work disability and work-related injuries. *Chest*. May 2015;147(5):1422-1428. doi:10.1378/chest.14-1949

21. Jurado-Gamez B, Guglielmi O, Gude F, Buela-Casal G. Workplace accidents, absenteeism and productivity in patients with sleep apnea. *Arch Bronconeumol*. May 2015;51(5):213-8. doi:10.1016/j.arbres.2014.07.003

22. Sjosten N, Vahtera J, Salo P, et al. Increased risk of lost workdays prior to the diagnosis of sleep apnea. *Chest*. Jul 2009;136(1):130-136. doi:10.1378/chest.08-2201

23. AlGhanim N, Comondore VR, Fleetham J, Marra CA, Ayas NT. The economic impact of obstructive sleep apnea. *Lung*. Jan-Feb 2008;186(1):7-12.

doi:10.1007/s00408-007-9055-5

24. Baldi I, Gulati A, Lorenzoni G, et al. Public health implications of obstructive sleep apnea burden. *Indian J Pediatr*. Sep 2014;81 Suppl 1:55-62. doi:10.1007/s12098-014-1539-8

25. De Benedetto M, Garbarino S, Sanna A. Obstructive sleep apnea (OSA): healthcare and social costs. *Med Lav*. Aug 28 2017;108(4):310-313. La Sindrome dell 'Apnea Ostruttiva nel sonno (OSAS): I costi sanitari e sociali.

doi:10.23749/mdl.v108i4.6411

26. Diaz K, Faverio P, Hospenthal A, Restrepo MI, Amuan ME, Pugh MJ. Obstructive sleep apnea is associated with higher healthcare utilization in elderly patients. *Ann Thorac Med.* Apr 2014;9(2):92-8. doi:10.4103/1817-1737.128854

27. Ding Q, Kryger M. Greater health care utilization and cost associated with untreated sleep apnea. *J Clin Sleep Med.* Jan 15 2020;16(1):5-6.

doi:10.5664/jcsm.8152

28. Gander P, Scott G, Mihaere K, Scott H. Societal costs of obstructive sleep apnoea syndrome. *N Z Med J*. Aug 27 2010;123(1321):13-23.

29. Hillman DR, Lack LC. Public health implications of sleep loss: the community burden. *Med J Aust*. Oct 21 2013;199(8):S7-10. doi:10.5694/mja13.10620

30. Hillman DR, Murphy AS, Pezzullo L. The economic cost of sleep disorders. *Sleep.* Mar 2006;29(3):299-305. doi:10.1093/sleep/29.3.299

31. Jennum P, Kjellberg J. Health, social and economical consequences of sleepdisordered breathing: a controlled national study. *Thorax*. Jul 2011;66(7):560-6. doi:10.1136/thx.2010.143958

32. Kao LT, Lee HC, Lin HC, Tsai MC, Chung SD. Healthcare Service Utilization by Patients with Obstructive Sleep Apnea: A Population-Based Study. *PLoS One*. 2015;10(9):e0137459. doi:10.1371/journal.pone.0137459

33. Kapur V, Blough DK, Sandblom RE, et al. The medical cost of undiagnosed sleep apnea. *Sleep*. Sep 15 1999;22(6):749-55. doi:10.1093/sleep/22.6.749

34. Kapur VK. Obstructive sleep apnea: diagnosis, epidemiology, and economics. *Respir Care*. Sep 2010;55(9):1155-67.

35. Krieger AC. Socio-economics perspectives of healthcare in sleep apnea. *Sleep Med.* Oct 2017;38:142-143. doi:10.1016/j.sleep.2017.09.006

36. Kryger MH, Roos L, Delaive K, Walld R, Horrocks J. Utilization of health care services in patients with severe obstructive sleep apnea. *Sleep*. Nov 1996;19(9 Suppl):S111-6. doi:10.1093/sleep/19.suppl\_9.s111

37. Morsy NE, Farrag NS, Zaki NFW, et al. Obstructive sleep apnea: personal, societal, public health, and legal implications. *Rev Environ Health*. Jun 26

2019;34(2):153-169. doi:10.1515/reveh-2018-0068

38. Reuveni H, Greenberg-Dotan S, Simon-Tuval T, Oksenberg A, Tarasiuk A. Elevated healthcare utilisation in young adult males with obstructive sleep apnoea. *Eur Respir J*. Feb 2008;31(2):273-9. doi:10.1183/09031936.00097907

39. Ronald J, Delaive K, Roos L, Manfreda J, Bahammam A, Kryger MH. Health care utilization in the 10 years prior to diagnosis in obstructive sleep apnea syndrome patients. *Sleep.* Mar 15 1999;22(2):225-9. doi:10.1093/sleep/22.2.225

40. Ronksley PE, Hemmelgarn BR, Heitman SJ, et al. Excessive daytime sleepiness is associated with increased health care utilization among patients referred for assessment of OSA. *Sleep.* Mar 1 2011;34(3):363-70. doi:10.1093/sleep/34.3.363

41. Sullivan F. Hidden Health Crisis Costing America Billions. Accessed February 10, 2021. <a href="https://aasm.org/advocacy/initiatives/economic-impact-obstructive-sleep-apnea/">https://aasm.org/advocacy/initiatives/economic-impact-obstructive-sleep-apnea/</a>

42. Tarasiuk A, Reuveni H. The economic impact of obstructive sleep apnea. *Curr Opin Pulm Med.* Nov 2013;19(6):639-44. doi:10.1097/MCP.0b013e3283659e1e

43. Wickwire EM, Tom SE, Vadlamani A, et al. Older adult US Medicare beneficiaries with untreated obstructive sleep apnea are heavier users of health care than matched control patients. *J Clin Sleep Med*. Jan 15 2020;16(1):81-89.

doi:10.5664/jcsm.8128

44. Kirsch DB, Yang H, Maslow AL, Stolzenbach M, McCall A. Association of
Positive Airway Pressure Use With Acute Care Utilization and Costs. *J Clin Sleep Med*.
Sep 15 2019;15(9):1243-1250. doi:10.5664/jcsm.7912

45. Chhatre S, Chang YHA, Gooneratne NS, Kuna S, Strollo P, Jayadevappa R.
Association between adherence to continuous positive airway pressure treatment and cost among medicare enrollees. *Sleep*. Jan 13 2020;43(1)doi:10.1093/sleep/zsz188
46. Derose SF, Zhou H, Huang BZ, Manthena P, Hwang D, Shi JM. Does Providing Positive Airway Pressure for Sleep Apnea Change Health Care Utilization? *Med Care*. Nov 2018;56(11):901-907. doi:10.1097/MLR.00000000000000963

47. Bahammam A, Delaive K, Ronald J, Manfreda J, Roos L, Kryger MH. Health care utilization in males with obstructive sleep apnea syndrome two years after diagnosis and treatment. *Sleep*. Sep 15 1999;22(6):740-7. doi:10.1093/sleep/22.6.740

48. Hwang D, Chang JW, Benjafield AV, et al. Effect of Telemedicine Education and Telemonitoring on Continuous Positive Airway Pressure Adherence. The Tele-OSA Randomized Trial. *Am J Respir Crit Care Med.* Jan 1 2018;197(1):117-126.

doi:10.1164/rccm.201703-0582OC

49. Chang J, Liang J, Becker K, et al. Patterns of long-term CPAP adherence: a 3year follow-up from the tele-OSA study. Journal: Conference Abstract. *Sleep*.

2019;42:A207-A208. doi:10.1093/sleep/zsz067.516

50. Physician Fee Schedule - January 2020 release. Centers for Medicare & Medicaid Services. Accessed March 28, 2021. <u>https://www.cms.gov/medicaremedicare-fee-service-paymentphysicianfeeschedpfs-relative-value-files/2020</u>

51. DMEPOS Fee Schedule. Centers for Medicare & Medicaid Services. Accessed March 28, 2021. <u>https://www.cms.gov/apps/ama/license.asp?file=/files/zip/20clabg1.zip</u>

52. Clinical Laboratory Fee Schelue. Centers for Medicare and Medicaid Services.

Accessed March 28, 2021. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-

Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files53. Medicaid

National Average Drug Acquisition Cost (NADAC). data.Medicaid.gov. Accessed March

28, 2021. <u>https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2020-01-</u> 29/d33b-b999

# 54. THE HCUP NATIONAL INPATIENT SAMPLE. Department of Health & Human

Services. Accessed March 28, 2021. https://www.hcup-

us.ahrq.gov/db/nation/nis/NIS\_Introduction\_2013.jsp

55. BLS Data Viewer. United States Department of Labor. Accessed March 28,

2021. https://beta.bls.gov/dataViewer/view/timeseries/CUUR0000SAM

56. Bang H, Tsiatis A. Estimating medical costs with censored data. *Biometrika*. 2000;87(2):329-343. doi:10.1093/biomet/87.2.329

57. Lin DY. Regression analysis of incomplete medical cost data. *Stat Med.* Apr 15 2003;22(7):1181-200. doi:10.1002/sim.1377

58. Glick HA DJ, Sonnad SS, Polsky D. . *Economic Evaluation in Clinical Trials*. Second Edition, ed. 2015.

59. Hwang D, Shakir N, Limann B, et al. Association of sleep-disordered breathing with postoperative complications. *Chest*. May 2008;133(5):1128-34.

doi:10.1378/chest.07-1488

60. Eurich DT, Achtymichuk KA, Johnson JA, Minhas-Sandhu JK, Lin M.

Development and Validation of an Index Score to Adjust for Healthy User Bias in

Observational Studies. J Popul Ther Clin Pharmacol. Nov 22 2017;24(3):e79-e89.

doi:10.22374/1710-6222.24.3.6

61. Kinjo M, Chia-Cheng Lai E, Korhonen MJ, McGill RL, Setoguchi S. Potential contribution of lifestyle and socioeconomic factors to healthy user bias in antihypertensives and lipid-lowering drugs. *Open Heart*. 2017;4(1):e000417. doi:10.1136/openhrt-2016-000417

62. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. *J Gen Intern Med.* May 2011;26(5):546-50. doi:10.1007/s11606-010-1609-1

63. Silverman SL, Gold DT. Healthy users, healthy adherers, and healthy behaviors? *J Bone Miner Res.* Apr 2011;26(4):681-2. doi:10.1002/jbmr.384

64. Delgado-Rodriguez M, Llorca J. Bias. *J Epidemiol Community Health*. Aug 2004;58(8):635-41. doi:10.1136/jech.2003.008466

65. O'Keeffe-Rosetti MC, Hornbrook MC, Fishman PA, et al. A standardized relative resource cost model for medical care: application to cancer control programs. *J Natl Cancer Inst Monogr.* 2013;2013(46):106-16. doi:10.1093/jncimonographs/lgt002

# **Figure Captions**

Figure 1. Mean Hours of PAP Use Over Time (Every 6 months) by PAP Adherence

Abbreviations: PAP = positive airway pressure. Mo = Month. *p*-value for trend in each

adherence group < 0.001

Figure 2. Mean Total Healthcare Costs Over Time (Every 6 months) by PAP Adherence

Abbreviations: PAP = positive airway pressure. Mo = Month. *p*-value for trend in each

adherence group < 0.001

Characteristics	Total (N=543)	Low Adherence	Moderate Adherence	High Adherence	<i>p</i> -value
		(N=285)	(N=120)	(N=138)	
Age, mean (SD)	50.0 (12.1)	49.3 (12.5)	50.9 (11.9)	50.8 (11.6)	0.34
Male, N (%)	321 (59)	155 (54)	73 (61)	93 (67)	0.04
Race/ethnicity, N (%)					
Asian Pacific Islander	42 (8)	23 (8)	11 (9)	8 (6)	0.01
Non-Hispanic Black	47 (9)	29 (10)	12 (10)	6 (4)	
Hispanic	215 (40)	123 (43)	48 (40)	44 (32)	
Non-Hispanic White	228 (42)	102 (36)	47 (39)	79 (57)	
Other	11 (2)	8 (3)	2 (2)	1 (1)	
Body Mass Index, mean (SD)	35.3 (7.5)	35.9 (7.4)	35.1 (8.6)	34.4 (6.4)	0.15
Body Mass Index Category, N (%)					
Normal	24 (4)	11 (4)	7 (6)	6 (4)	0.47
Overweight	110 (20)	53 (19)	29 (24)	28 (20)	
Moderately obese	279 (51)	147 (52)	58 (48)	74 (54)	
Severe obese	124 (23)	73 (26)	24 (20)	27 (20)	
Missing	6 (1)	1 (0.4)	2 (2)	3 (2)	
Medicaid indicator, N (%)	42 (8)	22 (8)	10 (8)	10 (7)	0.95
Smoking, N (%)					
Never/passive	340 (63)	187 (66)	65 (54)	88 (64)	0.31
Quit	156 (29)	73 (26)	46 (38)	37 (27)	
Active	36 (7)	19 (7)	7 (6)	10 (7)	
Missing	11 (2)	6 (2)	2 (2)	3 (2)	
Neighborhood median household income, mean (SD)	\$77,330	\$76,022	\$79,035	\$78,578	0.51
	(\$27,730)	(\$27,787)	(\$29,275)	(\$26,250)	
Neighborhood % of high school or less, mean (SD)	42.3 (15.8)	43.6 (16.0)	42.3 (15.4)	39.6 (15.2)	0.06
Marital status, N (%)					
Married/partner	357 (66)	174 (61)	84 (70)	99 (72)	0.09
Single/divorced/widow	146 (27)	90 (32)	25 (21)	31 (22)	

# Table 1. Participant Sociodemographic and Clinical Characteristics by PAP Adherence

Unknown	40 (7)	21 (7)	11 (9)	8 (6)	
Epworth Sleepiness Scale (ESS), mean (SD)	9.5 (5.2)	9.5 (5.3)	9.8 (5.2)	9.3 (5.0)	0.74
ESS category, N (%)					
<11	324 (60)	167 (59)	69 (58)	88 (64)	0.77
11-14.9	105 (19)	55 (19)	26 (22)	24 (17)	
15 or higher	103 (19)	55 (19)	24 (20)	24 (17)	
Missing	11 (2)	8 (3)	1 (1)	2 (1)	
Functional Outcomes of Sleep Questionnaire-10), mean (SD)	13.8 (4.5)	13.5 (4.5)	14.0 (4.5)	14.2 (4.5)	0.25
Missing, N (%)	26 (5)	18 (6)	11 (9)	9 (7)	
Apnea Hypopnea Index (AHI), mean (SD)	32.0 (25.7)	27.7 (24.9)	36.6 (27.2)	36.7 (24.7)	<0.001
AHI category, N (%)					
5-14.9	169 (31)	108 (38)	28 (23)	33 (24)	<0.001
15-29.9	155 (29)	88 (31)	34 (28)	33 (24)	
30 or higher	219 (40)	89 (31)	58 (48)	72 (52)	
Hypertension diagnosis, N (%)	214 (39)	109 (38)	50 (42)	55 (40)	0.81
Charlson Comorbidity Score (weighted), mean (SD)	0.9 (1.3)	0.9 (1.4)	0.7 (1.2)	0.9 (1.5)	0.38
Charlson Comorbidity Category, N (%)					
Diabetes without complications	112 (21)	65 (23)	25 (21)	22 (16)	0.26
Diabetes with complications	43 (8)	25 (9)	8 (7)	10 (7)	0.73
Chronic pulmonary disease	115 (21)	66 (23)	20 (17)	29 (21)	0.34
Peripheral vascular disease	32 (6)	16 (6)	6 (5)	10 (7)	0.72
Renal disease	28 (5)	13 (5)	3 (3)	12 (9)	0.06
Mild liver disease	32 (6)	23 (8)	7 (6)	2 (1)	0.03
Cancer	20 (4)	10 (4)	2 (2)	8 (6)	0.21
Congestive heart failure	8 (1)	4 (1)	2 (2)	2 (1)	0.98
Cerebrovascular disease	9 (2)	4 (1)	3 (3)	2 (1)	0.72
Myocardial Infarction	8 (1)	1 (0.4)	4 (3)	3 (2)	0.06
Rheumatic disease	4 (1)	3 (1)	0 (0)	1 (1)	0.53
Paraplegia/hemiplegia	3 (1)	1 (0.4)	2 (2)	0 (0)	0.16
Metastatic Carcinoma	3 (1)	3 (1)	0 (0)	0 (0)	0.26
Moderate/severe liver disease	1 (0.2)	1 (0.4)	0 (0)	0 (0)	0.64

Sleep clinic referral due to pre-operative assessment, N (%)	36 (7)	27 (9)	6 (5)	3 (2)	0.01
Medication adherence					
Antihypertensive medications, N (%)	255 (47)	132 (46)	58 (48)	65 (47)	
PDC, mean (SD)	0.92 (0.13)	0.92 (0.14)	0.92 (0.11)	0.93 (0.13)	0.64
Antidiabetic medications, N (%)	84 (15)	48 (17)	19 (16)	17 (12)	
PDC, mean (SD)	0.93 (0.09)	0.93 (0.10)	0.94 (0.09)	0.96 (0.04)	0.32
Statin, N (%)	173 (32)	84 (29)	43 (36)	46 (33)	
PDC, mean (SD)	0.92 (0.10)	0.92 (0.10)	0.89 (0.13)	0.94 (0.06)	0.02

Abbreviations: PAP = positive airway pressure, PDC = proportion of days covered. Statistically significant findings are bolded.

# Table 2. Adjusted Mean (SE) 6-Month Costs and Cost Savings Associated with Moderate or High PAP Adherence

# Stratified by Apnea Hypopnea Index (AHI)

	Adjusted Mean (SE)	Cost Savings (95% CI) from	Cost Savings (95% CI) from
	Cost	[Moderate vs Low] or	[High vs Moderate] Adherence
All			
Low	\$4,016 (\$315)		
Moderate	\$3,658 (\$369)	\$359 (-\$459, \$1,176), <i>p</i> =0.40	
High	\$3,162 (\$240)	\$854 (\$158, \$1,551), <i>p</i> =0.01	\$496 (-\$286, \$1,278), <i>p</i> =0.19
AHI: 5 to 14.9			
Low	\$4,170 (\$439)		
Moderate	\$2,913 (\$350)	\$1,257 (\$369, \$2,145), <i>p</i> =0.006	
High	\$3,187 (\$354)	\$983 (\$148, \$1,819), <i>p</i> =0.02	-\$274 (-\$1,014, \$465), <i>p</i> =0.47
AHI: 15 or higher			
Low	\$3,665 (\$282)		
Moderate	\$3,923 (\$429)	-\$258 (-\$1,155, \$639), <i>p</i> =0.56	
High	\$3,087 (\$242)	\$578 (-\$123, \$1,279), <i>p</i> =0.11	\$836 (-\$64, \$1,736), <i>p</i> =0.05

Abbreviations: PAP = positive airway pressure. Following covariates were included in the generalized linear models considering within-individual correlations and censoring weights: age, sex, race/ethnicity, body mass index, Medicaid, smoking status, hypertension, Charlson comorbidity, mild liver disease, prior 6-month cost, Apnea Hypopnea Index, pre-operative assessment, and time indicators (i.e. month 1-6, month 7-12, etc.). *p*-value for interaction (PAP adherence x AHI category) = 0.06. Statistically significant findings are bolded.

Туре	Low Adherence	Moderate Adherence	High Adherence	<i>P</i> -value Moderat e vs Low	<i>P</i> - value High vs Low	<i>P</i> -value High vs Moderat e	<i>P-valu</i> e Three group comparis on
Sleep-related office visit	\$70 (\$1)	\$69 (\$1)	\$67 (\$1)	0.32	0.02	0.25	0.06
Non-sleep-related office visit	\$922 (\$36)	\$981 (\$64)	\$806 (\$39)	0.41	0.04	0.04	0.03
Sleep-related DME	\$76 (\$3)	\$127 (\$6)	\$141 (\$6)	<0.001	<0.001	0.11	<0.001
Non-sleep-related DME	\$19 (\$7)	\$54 (\$48)	\$17 (\$10)	0.11	0.82	0.18	0.25
Hospitalization	\$4,004 (\$15,304)	\$1,234 (\$1,787)	\$179 (\$63)	0.63	0.001	0.01	0.003
Other hospital service	\$1,724 (\$3,623)	\$153 (\$90)	\$172 (\$109)	0.06	0.07	0.87	0.08
Pharmacy	\$1,644 (\$691)	\$1,640 (\$854)	\$2,930 (\$2,073)	0.99	0.24	0.19	0.41
Laboratory	\$218 (\$14)	\$184 (\$18)	\$158 (\$14)	0.08	0.002	0.22	0.006
Emergency department	\$54 (\$7)	\$61 (\$12)	\$36 (\$7)	0.56	0.11	0.06	0.15
Radiology	\$104 (\$10)	\$95 (\$14)	\$100 (\$13)	0.58	0.78	0.79	0.85
Phone	\$59 (\$3)	\$51 (\$4)	\$41 (\$3)	0.08	<0.001	0.03	<0.001

### Table 3. Adjusted Mean (SE) Six-Month Healthcare Costs by Type of Healthcare Use and PAP Adherence

Abbreviations: PAP = positive airway pressure; DME = durable medical equipment. Following covariates were included in the generalized linear models considering within-individual correlations and censoring weights: age, sex, race/ethnicity, body mass index, Medicaid, smoking status, hypertension, Charlson comorbidity, mild liver disease, prior 6-month cost, Apnea Hypopnea Index, pre-operative assessment, and time indicators (i.e. month 1-6, month 7-12, etc.). Statistically significant findings are bolded.



